Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-arm, Phase II Clinical Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab Under the Guidance of Transcriptome Profiling.

NCT06513221 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06513221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06513221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-arm, Phase II Clinical Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab Under the Guidance of Transcriptome Profiling.
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 25, 2024
Completion date
April 12, 2027
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer